Jack is an Associate Professor in the Department of Pharmacology and Clinical Pharmacology at the University of Auckland in New Zealand. Jack's research experience includes drug metabolism and inhibitor discovery and design for enzymes that synthesize lipid signalling molecules including prostaglandin D2 synthase and phosphatidylinositol-3 kinases. Jack's research combines computational methods for ligand discovery with biochemical and cell based systems.

André McKenzie is a postdoctoral research associate at the Kassiou Drug Discovery Laboratory at the University of Sydney. His current work focuses on investigating the expression and functionality of purinergic receptors on induced-pluripotent stem cell derived cell types sourced from Alzheimer's disease and amyotrophic lateral sclerosis patients and the translatability of these cell models for drug discovery. He is the ECR representative for the ANZ Purine Club. His

Robert Vandenberg has been an academic in Pharmacology at the University of Sydney since 1995 and appointed as Professor in 2010. Robert has had a long standing interest in understanding mechanisms of drug action at neurotransmitter transporters. His presentation is based on a large collaborative project that incorporates medicinal chemistry, in vitro analysis of transporter function, structural biology, pharmacokinetic analysis and animal behavioural studies to identify glycine transport inhibitors for development as a therapeutic for neuropathic pain.

Li Zitong is a PhD candidate in Biomedical Sciences at The Chinese University of Hong Kong, supervised by Prof. John A. Rudd. Her research centers on disease mechanisms and the development of novel pharmacological therapies. She is currently studying the emetic, behavioral, physiological, and therapeutic aspects of motion sickness. Li Zitong has authored or co authored more than five peer reviewed publications and has presented at international scientific meetings. At WCP 2026, she will present multidimensional responses to motion (including emetic and autonomic outcomes) and the evaluation of related drugs in Suncus murinus.

Dr Hellyer is an EMCR researcher at the Monash Institute of Pharmaceutical Sciences, and it Deputy lab head of the Neuropharmacology lab within Drug Discovery Biology. His works focuses on the molecular pharmacology of GPCRs involved in neurophysiology and neuropathophysiology. In particular, Dr Hellyer is interested in the impact of single nucleotide variants found in patients populations, how they contribute to disease aetiology and how they potentially affect drug action on through changing receptor function. Dr Hellyer has published 21 peer reviewed journal articles and 1 book chapter, acting as a Chief Investigator on competitive grants worth $1.4 million.

Dr Nair is a Group Leader of the Computational and Molecular Pharmacology Laboratory at the Flinders Health and Medical Research, Flinders University. His research focuses on drug discovery for neuropsychiatric disorders and cancer. His research integrates computational medicinal chemistry, pharmacogenomics, and experimental pharmacology to drive advancements in precision medicine. He has published > 50 peer-reviewed articles and has attracted over $5 million in research funding through various funding schemes, including NHMRC, MRFF, Cancer Council etc. He has won > 10 young investigator awards, including Building Research Leaders Award by Adelaide University, CERTARA New Investigator Award by the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists and Flinders University Vice-Chancellor's Award for Early Career Researchers.